fingolimod
Selected indexed studies
- Fingolimod: therapeutic mechanisms and ocular adverse effects. (Eye (Lond), 2017) [PMID:27886183]
- Fingolimod in pediatric-onset multiple sclerosis. (Neurol Sci, 2021) [PMID:33945033]
- Fingolimod: Lessons Learned and New Opportunities for Treating Multiple Sclerosis and Other Disorders. (Annu Rev Pharmacol Toxicol, 2019) [PMID:30625282]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Fingolimod: therapeutic mechanisms and ocular adverse effects. (2017) pubmed
- Fingolimod in pediatric-onset multiple sclerosis. (2021) pubmed
- Fingolimod: Lessons Learned and New Opportunities for Treating Multiple Sclerosis and Other Disorders. (2019) pubmed
- Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis. (2017) pubmed
- Fingolimod ameliorates amyloid deposition and neurodegeneration in APP/PS1 mouse model of Alzheimer's disease. (2025) pubmed
- Discovery of fingolimod based on the chemical modification of a natural product from the fungus, Isaria sinclairii. (2020) pubmed
- Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy. (2012) pubmed
- Therapeutic Potential of Fingolimod on Psychological Symptoms and Cognitive Function in Neuropsychiatric and Neurological Disorders. (2024) pubmed
- Fingolimod: a review of its mode of action in the context of its efficacy and safety profile in relapsing forms of multiple sclerosis. (2016) pubmed
- Severe Exacerbation of Multiple Sclerosis Following Withdrawal of Fingolimod. (2019) pubmed